Hepatitis C virus-resistant “two-pronged approach,”
A diameter of less than 80 nm virus, will imperceptibly “eaten” the liver would lead to cirrhosis, liver cancer, and so the deadly disease, but this tiny little virus, were known, it is hepatitis C virus.
Shanghai Huashan Hospital affiliated to Fudan University Professor Xin-Hua Weng, hepatitis C virus and Japanese encephalitis virus, influenza virus, the same is an RNA virus.
Human hepatitis C virus infection after the initial symptoms was not obvious, is often overlooked.
But the virus on the liver damage has been continued, so a healthy liver, hepatitis C is considered the silent killer.
Hepatitis C is caused by cirrhosis of the liver disease, liver disease, one of the highest fatality rate, according to the World Health Organization (WHO) report, the global death toll from hepatitis C cause of death in the infectious diseases section 10, and cancer-related diseases, hepatitis C has been listed in third place.
Xiao Bian recommended: hepatitis C risk should be a long process, precisely because of its concealed lead to many patients do not know their own illness, resulting in delay treatment, resulting in life-long regret. With the hepatitis C community on the importance, more and more people are beginning to pay attention to this silent killer Hepatitis C … … [more information, please "" "" Expert Forum: the dangers and prevention of hepatitis C]
“Two-pronged approach,” Treatment of hepatitis C
To deal with hepatitis C, antiviral treatment is the key, anti-virus “arms” must also be sharp.
By the Chinese Medical Association and the Infectious Diseases Liver credits credits will be issued in 2004, “Hepatitis C Prevention Guide” clearly states that interferon combined with ribavirin for hepatitis C treatment is effective anti-viral treatment.
The emergence of pegylated interferon is also greatly enhanced the efficacy of a number of large-scale clinical trial results show that pegylated interferon α-2a (Pegasys) combined with ribavirin therapy, Qi Cheng Liu Cheng to the patient access to effectively remove the virus and eventually cure the disease.
People’s Liberation Army 302 Hospital, Professor Zhang Hongfei Ge, “pegylated interferon α-2a (Pegasys) combined with ribavirin, known as the classic joint.”
Pegylated interferon α-2a (Pegasys) and ribavirin, “two-pronged approach,” Treatment of hepatitis C has become the standard treatment program in 2007 at the annual meeting of the European Liver research data further proof polyethylene 2 Aging of interferon α-2a (Pegasys) in the treatment of patients with hepatitis C and effective, curative stable, relapse is low.
AASLD 2007 at the annual meeting of the REPEAT study, so that those who start treatment failure patients have also seen the hope of cure.
The findings show that the original PEG-IFN α-2b treatment of patients do not respond by once weekly pegylated interferon α-2a (Pegasys) combined daily ribavirin therapy, Many of them achieved a viral removal.
REPEAT is a landmark study, which has greatly enriched the first treatment failure in patients with knowledge.
In order to allow more patients to achieve cure hope for hepatitis C, as a leader in the field of viral hepatitis treatment, Roche has been committed to new drugs to treat hepatitis C research and development, The company has three small-molecule anti-viral compounds, is developing online .
According to the American Liver Diseases annual meeting of the reports indicate that one of the small molecule compounds and pegylated interferon α-2a (Pegasys) has synergistic antiviral activity, indicating broad prospects for the treatment of hepatitis C 2.
Professor Zhang Hongfei said: “As long as early detection, early treatment, hepatitis C can be cured. The current treatment level can help cure diseases, most patients believe that with the continuous deepening of the study and optimization of new treatment programs, most of even was achieved in all patients will be cured of their illnesses hope. “